Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abvc Biopharma Inc (NQ: ABVC )

0.6590 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EDT, Sep 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.6590
Bid (Size) 0.6510 (58)
Ask (Size) 0.6885 (1)
Prev. Close 0.6590
Today's Range 0.6590 - 0.6590
52wk Range 0.6000 - 3.350
Shares Outstanding 24,420,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024
ABVC BioPharma just reported results for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-45.08%
-45.08%
1 Month
-4.96%
-4.96%
3 Month
-15.10%
-15.10%
6 Month
-46.85%
-46.85%
1 Year
-44.15%
-44.15%

More News

Read More
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
Via NewMediaWire
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024
Via InvestorPlace
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
Via NewMediaWire
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
Via NewMediaWire
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
Via TheNewswire.com
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
Via NewMediaWire
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
Via NewMediaWire
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
Via NewMediaWire
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Via NewMediaWire
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Via TheNewswire.com
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Via NewMediaWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Via NewMediaWire
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Via TheNewswire.com
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why ABVC BioPharma Stock Is Up Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.